• Home
  • About KinaseCentral

Kinase News

Entries RSS | Comments RSS
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines
  • Tags

    AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
  • Providing a resource for information on kinase inhibitors

ImClone initiate randomized Phase II trial of IMC-A12 in breast cancer

Posted on September 26, 2008 by crimsoncanary

ImClone Systems have initiated a phase II clinical trial of its anti-IGF-1R MAb IMC-A12 in women with advanced breast cancer

Filed under: Uncategorized | Tagged: IGF-1R, IGF-R1, IMC-A12, IMCA12, ImClone, kinase, Monoclonal, Phase II

« Ligand to acquire Pharmacopeia Roche to initiate Phase II trial of IGF-1R MAb R1507 in NSCLC »
  • Calendar

    • September 2008
      M T W T F S S
      « Aug   Oct »
      1234567
      891011121314
      15161718192021
      22232425262728
      2930  
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer